找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Kala Azar in South Asia; Current Status and S E. Noiri,T.K. Jha Book 2016Latest edition Springer International Publishing 2016 Neglected Tr

[復(fù)制鏈接]
樓主: Malicious
31#
發(fā)表于 2025-3-26 23:28:14 | 只看該作者
http://image.papertrans.cn/k/image/541720.jpg
32#
發(fā)表于 2025-3-27 04:54:16 | 只看該作者
33#
發(fā)表于 2025-3-27 08:30:17 | 只看該作者
linical, epidemiological and entomological aspects.Includes .Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease?first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical di
34#
發(fā)表于 2025-3-27 10:07:26 | 只看該作者
35#
發(fā)表于 2025-3-27 14:47:47 | 只看該作者
36#
發(fā)表于 2025-3-27 20:43:45 | 只看該作者
Vaccine Development for Leishmaniasisalian hosts, enabling a multilateral prevention strategy. Furthermore, the use of a vaccine is now not only for prevention but also for treatment. Within this manuscript we review background information, the current status, and the future direction of vaccine development for leishmaniasis.
37#
發(fā)表于 2025-3-27 23:53:48 | 只看該作者
Potentiality of Urinary L-FABP Tests to Kala-Azar Disease Managementrinary immuno-chromatography dipstick test for point of care use in endemic areas. We expect that a FABP1 dipstick test will serve as a triage marker in disease monitoring of VL. In addition, this chapter introduces the impact of FABP1 on predicting survival in septic acute kidney injury and the clinical interpretation of FABP1 measurements in VL.
38#
發(fā)表于 2025-3-28 04:42:45 | 只看該作者
39#
發(fā)表于 2025-3-28 09:04:20 | 只看該作者
40#
發(fā)表于 2025-3-28 12:11:39 | 只看該作者
Changes of , Antigens in Kala-Azar Patients’ Urine After Treatment than that with nested PCR (88 %), but higher than that with KAtex (48 %) before the treatment, and it reduced more slowly than that with the others after the treatment. As the urine ELISA gives CA levels quantitatively, it will be useful to evaluate the efficacy of the treatments used and for surveillance of drug resistance.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 19:03
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
东宁县| 谷城县| 建昌县| 衡南县| 瑞昌市| 任丘市| 鹤峰县| 苏尼特右旗| 兰考县| 合阳县| 信阳市| 美姑县| 克山县| 镇平县| 新乐市| 靖江市| 于都县| 鹤壁市| 沾化县| 商水县| 绥化市| 正镶白旗| 如东县| 额济纳旗| 金昌市| 望江县| 射洪县| 东莞市| 蚌埠市| 甘洛县| 五台县| 淳化县| 怀集县| 青浦区| 尖扎县| 岐山县| 太保市| 武冈市| 天门市| 北流市| 赤水市|